ANALISIS BIAYA DAN KUALITAS HIDUP PASIEN RAWAT JALAN DM TIPE 2 DENGAN TERAPI GLIQUIDONE DIBANDINGKAN GLIMEPIRIDE DI RSUD SURAKARTA TAHUN 2021

Inaratul Rizkhy Hanifah; Ela Dewi Puspita Sari; Samuel Budi Harsono

doi:10.24843/JFU.2022.v11.i02.p03

Inaratul Rizkhy Hanifah Universitas Setia Budi
Ela Dewi Puspita Sari Program Studi S1 Farmasi, Universitas Setia Budi, Surakarta
Samuel Budi Harsono Program Studi S1 Farmasi, Universitas Setia Budi, Surakarta

DOI: https://doi.org/10.24843/JFU.2022.v11.i02.p03

Abstract

Diabetes Mellitus type 2 is a degenerative disease suffered by patients for life. WHO estimates that Indonesia's number of people with diabetes will be around 21.3 million in 2030. Poor blood sugar control in DM patients impacts the decreasing quality of life and increasing health costs. The aim of this study was to analyze the cost of gliquidone therapy compared to glimepiride and the quality of life of outpatients with type 2 DM at the Surakarta Hospital in 2021. The research was conducted using a cross-sectional study design. The sample in this study was obtained through the purposive sampling method with patients who met the inclusion criteria. Cost analysis was carried out by calculating direct medical and non-medical costs, followed by calculating the RUB value to determine which therapy had the most cost-utility. This study was conducted in August-September 2021. Cost data includes total medical costs from hospitals and transportation costs. Quality of life value in this study was measured using the D-QOL questionnaire. The results showed that the RUB value was Rp. 5,389,203; U = 0.749 while glimepiride was Rp. 4,117.949; U = 0.754. The sensitivity test results showed that the cost of non-ADO drugs had the longest range, so it became the most influential factor. More cost-utility compared to gliquidone.

Keywords: Oral antidiabetic, CUA, Diabetes Mellitus, Quality of life

Downloads

Download data is not yet available.

References

Adikusuma, W., Perwitasari, D. A., & Supadmi, W. 2016. Pengukuran Kualitas Hidup Pasien Diabetes Melitus Tipe 2 yang Mendapat Antidiabetik Oral di Rumah Sakit PKU Muhammadiyah Bantul Yogyakarta. Jurnal Ilmiah Ibnu Sina, 1(1), 1-8.
American Diabetes Association (ADA). 2014. Diagnosis And Classification Of Diabetes Mellitus. Diabetes Care, 37(1), 81–90
Baroroh, F., & Solikah, W. Y. 2016. Analisis biaya terapi Diabetes Melitus tipe 2 di Rumah Sakit PKU Muhammadiyah Bantul Yogyakarta. Jurnal Farmasi Sains dan Praktis, 1(2), 11-21.
Fatimah, R. N. 2015. Diabetes melitus tipe 2. Jurnal Majority, 4(5).
Hartanto, D., & Mulyani, T. T. 2017. Gambaran Biaya Pasien Diabetes Melitus Tipe 2 Dengan Terapi Antidiabetik Oral Di RSUD Ulin Banjarmasin. Jurnal Ilmiah Ibnu Sina, 2(1): 109-116.
Muliyani, N. I. 2019. Karakteristik Pasien Diabetes Mellitus Tipe 2 Yang Mendapatkan Terapi Antidiabetik Oral di Rsud Dr. H. Moch. Ansari Saleh Banjarmasin. Jurnal Kajian Ilmiah Kesehatan Dan Teknologi, 1(1): 11-16.
Prihandiwati, E., Pratiwi, M. D., Ayuchecaria, N., Ariani, N., Aisyah, N., & Mardiana, M. 2019. Kualitas Hidup Pasien Kanker Payudara Di Ruang Edelweis Rsud Ulin Banjarmasin. Jurnal Ilmiah Ibnu Sina, 4(1): 176-185.
Ramadhan, N., & Marissa, N. 2015. Karakteristik Penderita Diabetes Mellitus Tipe 2 Berdasarkan Kadar Hba1c Di Puskesmas Jayabaru Kota Banda Aceh.
Swastini, D. A., Putri, S. A., Rudiarta, N. M., & Wiryanthini, I. A. D. (2016). Gambaran Terapi Layanan Jkn pada Pasien Hipertensi Stage I dan Diabetes Melitus Tipe 2 di Unit Rawat Jalan Rumah Sakit Udayana. Jurnal Farmasi Udayana, 5(1), 279781.
Tjandrawinata, R. R. 2016. Peranan Farmakoekonomi dalam Penentuan Kebijakan yang Berkaitan dengan Obat-Obatan. Jurnal Medicinus, 29(1)